FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 421 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Catumaxomab November 12, 2024 Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... August 27, 2021 Taking pride in all of our researchers November 18, 2021 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... February 3, 2022 Load more HOT NEWS Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... Autumn and Letting Go Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... Detecting multiple cancers with a ‘simple’ blood test: Where are we?
